9 citations
,
January 2017 in “Farmacia” This review discusses the safety of finasteride for male androgenic alopecia and benign prostatic hyperplasia, concluding it remains a viable option due to synergistic effects with other treatments and predictive measures for side effect risk.
14 citations
,
January 2020 in “Archivio Italiano di Urologia e Andrologia” This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.
33 citations
,
July 2009 in “Therapeutics and Clinical Risk Management” This review discusses the use of finasteride for treating benign prostatic hyperplasia and highlights its potential for reducing prostate size, symptom control, and lowering the risk of surgery and urinary retention.
14 citations
,
November 2008 in “Expert opinion on drug metabolism & toxicology” This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.
March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” This analysis concluded that finasteride effectively reduces prostate size and urinary symptoms in benign prostatic hyperplasia, offering a favorable safety profile and versatility as a treatment option.